ANTX NASDAQ
AN2 Therapeutics, Inc.
1W: +8.4%
1M: -22.9%
3M: -23.1%
YTD: +247.8%
1Y: +229.9%
3Y: -74.2%
$3.86
+0.23 (+6.34%)
Weekly Expected Move ±11.9%
$3
$3
$4
$4
$4
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 6.39.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$145.7M
52W Range1-7.19
Volume239,616
Avg Volume290,897
Beta-0.98
Dividend—
Analyst Ratings
Company Info
CEOEric E. Easom
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2022-03-25
Websitean2therapeutics.com
1800 El Camino Real
Menlo Park, CA 94025
US
Menlo Park, CA 94025
US
650-331-9090
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Marks Gilbert Lynn | A-Award | 2,283 | — | 2026-10-12 |
| Martin Patricia A. | A-Award | 389 | — | 2026-10-12 |
| Aziz Kabeer | A-Award | 2,465 | — | 2026-10-12 |
| Trenor Cameron C. II | A-Award | 116,667 | — | 2026-09-15 |
| Trenor Cameron C. II | A-Award | 233,333 | $5.36 | 2026-09-15 |